HALOZYME THERAPEUTICS, INC. and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. as Trustee INDENTURE Dated as of November 18, 2019 1.25% Convertible Senior Notes due 2024Indenture • November 18th, 2019 • Halozyme Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
INDENTURE, dated as of November 18, 2019, between Halozyme Therapeutics, Inc., a Delaware corporation, as issuer (the “Company”), and The Bank of New York Mellon Trust Company, N.A., not in its individual capacity but solely as trustee, registrar, paying agent and conversion agent (the “Trustee”).
